Survival curves of NPM1-mutated AML patients (NK vs AK) from the MLL. (A) No significant differences in OS between NPM1-mutated AML with NK (n = 328) and NPM1-mutated cases with AK (n = 62) are observed (P = .804). (B) No significant differences in EFS between NPM1-mutated AML with NK (n = 328) and NPM1-mutated cases with AK (n = 62) are observed (P = .849). (C) No significant differences in OS between NPM1-mutated/FLT3-ITD⁻ AML with NK (n = 197) and NPM1-mutated cases with AK (n = 44) are observed (P = .075). (D) No significant differences in EFS between NPM1-mutated/FLT3-ITD⁻ AML with NK (n = 197) and NPM1-mutated cases with AK (n = 44) are observed (P = .176).